GlassScriptPhysician profile
Lee M Blatstein
NPI 1346233269
$3,579.92
in general payments reported to CMS, 2019-2025
25 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $92.96 · 2021: $62.16 · 2022: $91.66 · 2023: $1,239 · 2024: $1,110 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.26 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $652.16 | 2019-2025 | Erleada |
| Astellas Pharma US INC | $533.12 | 2019-2025 | Xtandi, Veozah |
| Sumitomo Pharma America, INC. | $383.51 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $314.93 | 2019-2024 | Lupron Depot |
| 180 Medical, INC. | $244.00 | 2023-2025 | Gentlecath |
| Pfizer INC. | $222.06 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $215.50 | 2022-2023 | |
| Convatec INC. | $177.19 | 2023-2024 | |
| Teleflex LLC | $120.92 | 2023-2025 | Urolift |
| Ferring Pharmaceuticals INC. | $108.71 | 2024-2025 | Adstiladrin |
| Myriad Genetic Laboratories, INC. | $98.69 | 2021-2024 | Prolaris |
| Blue Earth Diagnostics | $75.36 | 2019-2024 | |
| Endo Pharmaceuticals INC. | $58.77 | 2019 | |
| Boston Scientific Corporation | $52.17 | 2019-2023 | Rezum Generator |
| C. R. Bard, INC. & Subsidiaries | $44.06 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.75 | 2019-2020 | |
| Coloplast Corp | $36.49 | 2019-2024 | |
| Progenics Pharmaceuticals, INC. | $34.24 | 2023 | Pylarify |
| Tolmar Pharmaceuticals, INC. | $34.01 | 2019 | |
| Neotract INC. | $33.37 | 2019-2020 | |
| Endo USA, INC. | $23.52 | 2024 | Xiaflex |
| Alnylam Pharmaceuticals INC. | $20.40 | 2023 | Oxlumo |
| Urogen Pharma, INC. | $19.71 | 2023 | Jelmyto |
| Novartis Pharmaceuticals Corporation | $18.28 | 2024 | |
| Immunitybio, INC. | $17.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Blatstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.